Abstract

The recombinant human growth hormone has been used for about 40 years and is administered as a single daily dose. Long-acting growth hormones are developed to enhance therapy adherence and reduce therapy load. Somatrogon, the first and only weekly growth hormone in our country, has been well tolerated by patients, and no serious adverse events have occurred. Somatrogon obtained a license in our country on March 9, 2023, and was reimbursed on May 17, 2024. The recommended dosage is once a week, 0.66 mg/kg/dose on the same day of the week, available for use in the forms of 24 mg and 60 mg. Somatrogon is expected to provide an advantage in ease of weekly administration and treatment load and improve treatment compliance. It is also essential to closely monitor the long-term studies and the treatment’s effectiveness, safety, and adherence.